ChemoCentryx Inc (OQ:CCXI)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 850 Maude Ave
Tel: 1-650-2102900
IR: See website
Key People
Thomas J. Schall
Chairman of the Board, President, Chief Executive Officer
Susan M. Kanaya
Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary, IR Contact Officer
Rajinder Singh
Senior Vice President - Research
Markus J. Cappel
Chief Business Officer, Treasurer
Business Overview
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Financial Overview
For the nine months ended 30 September 2019, ChemoCentryx Inc revenues decreased 22% to $26.1M. Net loss increased 47% to $40M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 7% to $51.1M (expense), General and administrative increase of 16% to $17.2M (expense).
Employees: 76 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $2,234M as of Sep 30, 2019
Annual revenue (TTM): $35.41M as of Sep 30, 2019
EBITDA (TTM): -$52.22M as of Sep 30, 2019
Net annual income (TTM): -$50.75M as of Sep 30, 2019
Free cash flow (TTM): -$65.75M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 58,268,567 as of Oct 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization